US 12,240,870 B2
Sequencing method for CAR T cell therapy
Richard Messmann, Brighton, MI (US); Christopher Paul Leamon, West Lafayette, IN (US); Haiyan Chu, West Lafayette, IN (US); Yingjuan June Lu, West Lafayette, IN (US); Philip Stewart Low, West Lafayette, IN (US); Michael C. Jensen, Bainbridge Island, WA (US); James Matthaei, Seattle, WA (US); Navin Robert Charles Pinto, Seattle, WA (US); and Julie Ruggieri Park, Seattle, WA (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US); Endocyte, Inc, West Lafayette, IN (US); and Seattle Children's Hospital, Seattle, WA (US)
Appl. No. 16/971,801
Filed by Purdue Research Foundation, West Lafayette, IN (US); ENDOCYTE, INC., West Lafayette, IN (US); and SEATTLE CHILDREN'S HOSPITAL, Seattle, WA (US)
PCT Filed Feb. 22, 2019, PCT No. PCT/US2019/019191
§ 371(c)(1), (2) Date Aug. 21, 2020,
PCT Pub. No. WO2019/165237, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/634,573, filed on Feb. 23, 2018.
Claims priority of provisional application 62/656,265, filed on Apr. 11, 2018.
Claims priority of provisional application 62/724,345, filed on Aug. 29, 2018.
Claims priority of provisional application 62/736,730, filed on Sep. 26, 2018.
Prior Publication US 2021/0346431 A1, Nov. 11, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 47/55 (2017.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01)
CPC A61K 47/551 (2017.08) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464404 (2023.05); A61K 39/4646 (2023.05); A61P 35/00 (2018.01); C07K 14/705 (2013.01); A61K 2239/38 (2023.05)] 14 Claims
OG exemplary drawing
 
1. A method of treating a patient for cancer, the method comprising
i) administering to the patient at least one dose of a chimeric antigen receptor T cell (CAR T cell) composition comprising CAR T cells comprising a chimeric antigen receptor (CAR) directed to a targeting moiety; and
ii) administering to the patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to the targeting moiety by a linker, wherein the small molecule ligand is folate and wherein the targeting moiety is fluorescein, or a pharmaceutically acceptable salt thereof, fluorescein isothiocyanate (FITC), or NHS-fluorescein, and wherein the compound, or the pharmaceutically acceptable salt thereof, is administered in at least a first dose escalation sequence and a second dose escalation sequence, wherein a full dose of the compound, or the pharmaceutically acceptable salt thereof, is 10 μg/kg to 50 μg/kg of the compound, or the pharmaceutically acceptable salt thereof;
wherein the first dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a first two-week cycle; and
wherein the second dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a second two-week cycle,
whereupon the patient is treated for cancer, and wherein the patient is a human.